« Previous
Next »
Titles
- FAQs: what's the latest on IPAB?1
- FDA categorization of investigational device exemption (IDE) devices to assist the Centers for Medicare and Medicaid Services (CMS) with coverage decisions: guidance for sponsors, clinical investigators, industry, institutional review boards, and Food and Drug Administration staff1
- FDA deems certain tobacco products subject to FDA authority, sales and distribution restrictions, and health warning requirements for packages and advertisements: (revised)1
- FDA medical device reviews: evaluation is needed to assure requests for additional information follow a least burdensome approach : report to Congressional requestors1
- FDA oversight1
- FDA oversight of tobacco manufacturing establishments1
- FDA should further integrate its review of cybersecurity into the premarket review process for medical devices1
- FH Healthcare Indicators (TM) and FH Medical Price Index (TM): a new view of place of service trends and medical pricing1
- FY 2018 medical device user fee small business qualification and certification: guidance for industry, Food and Drug Administration staff and foreign governments1
- Facility definition under Section 503B of the Federal Food, Drug, and Cosmetic Act1
- Facility quality and safety1
- Factors affecting states' ability to respond to federal Medicaid cuts and caps: which states are most at risk?1
- Factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications: guidance for industry and Food and Drug Administration staff1
- Family consequences of detention/deportation: effects on finances, health, and well-being1
- Federal Medicaid policy1
- Federal disaster assistance: FEMA's progress in aiding individuals with disabilities could be further enhanced : report to Congressional requesters1
- Federal employees health benefits program: enrollment remains concentrated despite more plan offerings, and effects of adding plan types are uncertain : report to the ranking member, Committee on Oversight and Government Reform, House of Representatives1
- Federal health insurance exchange: CMS needs to ensure complete, accurate data on terminations of coverage for nonpayment of premiums : report to Congressional requesters1
- Federal legislation to address the opioid crisis: Medicaid provisions in the SUPPORT Act1
- Federal low-income programs: eligibility and benefits differ for selected programs due to complex and varied rules : report to the Chairman, Committee on the Budget, U.S. Senate1